76 results about "Antibody conjugate" patented technology

This invention discloses a quantitative test strip for HBV PreS1 antibody based on the AIE molecule, its preparation method, and its applications, relating to the fields of molecular biology, immunology, and biodetection technology. The test strip includes a sample pad, a labeling pad, a nitrocellulose membrane (NC membrane), an absorbent pad, and a base plate. The NC membrane detection line is coated with HBV PreS1 antigen to capture PreS1 antibodies in the sample. The labeling pad contains an immobilized Anti-Human IgG antibody conjugated to the AIE molecule, which binds to the PreS1 antibodies in the sample to form an immune complex. The test strip of this invention enables rapid detection of PreS1 antibodies and achieves enhanced fluorescence in the detection results. Combined with a fluorescence reader or fluorescence card reader, the detection results can be digitally and quantitatively analyzed. It is simple to operate, rapid in detection, and significantly improves detection sensitivity and enables quantitative analysis.

This invention discloses an antibody targeting a specific protein of *Lactobacillus* and its applications. The monoclonal antibody of this invention is any one of monoclonal antibody 1B3, monoclonal antibody 3B5, monoclonal antibody 2E5, and monoclonal antibody 3D8, which respectively recognize proteins Srt A, Cps C, ENO 1, and Fts Z. The magnetic bead antibody conjugate is prepared by conjugating the monoclonal antibody with activated carboxyl magnetic beads. The magnetic bead antibody conjugate of this invention can specifically enrich *Lactobacillus* bacteria with high enrichment efficiency and simple operation. It can be applied to the identification of metabolites of *Lactobacillus* bacteria, as well as their qualitative and quantitative analysis.

The present application relates to the technical field of antibody conjugated drugs, in particular to a drug conjugate with sustained-release property, an antibody conjugated drug and application thereof. The drug conjugate Payload is a payload selected from a drug molecule with cytotoxicity; X is a heteroatom in the payload, selected from O or N; R4 and R5 are independently selected from hydrogen, an alkyl group or other chemical modification groups; R1, R2, R3 and R6 are independently selected from hydrogen, an amino group, a group containing an ether bond, a hydrophilic group, a halogen, an alkyl group or other chemical modification groups; and Glu is a glucuronic acid group. The present application has the advantages of achieving sustained-release effect, increasing stability, avoiding possible non-specific rupture of carbamate bonds in in-vivo circulation, improving the half-life of ADC drugs in blood circulation, reducing toxicity and increasing drug efficacy, and achieving more effective and safe treatment effect due to the sustained-release mechanism which maintains local toxin concentration in a more reasonable killing interval and reduces systemic toxic side effects.

Provided herein are immune stimulating anti-HBsAg antibody conjugates, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an HBV infection.

This invention discloses an antibody against a specific protein of *E. rectum*, a magnetic bead antibody-conjugate, and their applications. The monoclonal antibody is either monoclonal antibody 4D3F6H7 or monoclonal antibody 5C8E7D6. The amino acid sequences of the heavy chain variable region and light chain variable region of monoclonal antibody 4D3F6H7 are shown in SEQ ID NO: 5 and SEQ ID NO: 6, respectively. The amino acid sequences of the heavy chain variable region and light chain variable region of monoclonal antibody 5C8E7D6 are shown in SEQ ID NO: 7 and SEQ ID NO: 8, respectively. The magnetic bead antibody-conjugate is obtained by conjugating the monoclonal antibody with activated carboxyl magnetic beads. The magnetic bead antibody-conjugate of this invention can specifically enrich *E. rectum* with high enrichment efficiency and simple operation. It can be applied to the identification of *E. rectum* metabolites, as well as their qualitative and quantitative analysis.

Provided is a linker-containing antibody drug conjugate. Also involved are a pharmaceutical composition comprising the antibody conjugate, a use of a linker, and a use of the antibody conjugate in the preparation for a drug for preventing and / or treating diseases.

The application discloses a nano-antibody (also known as single-domain antibody) conjugated photosensitizer targeting HER2, a preparation method of the photosensitizer and application of the photosensitizer in tumor photodynamic therapy. The photosensitizer is shown in a general formula (I). In the photosensitizer, the nano-antibody (N HER2 ) serving as a targeting ligand is connected with a photosensitive moiety (PS) through a catalytic reaction mediated by a transglutaminase (MTGase). Research finds that the anti-HER2 nano-antibody conjugated photosensitizer molecule has good cell killing selectivity and tumor enrichment capacity, and can remove a subcutaneous tumor of a mouse with high HER2 expression in one administration. HER2 -PEG 1K -PS (I).

The invention relates to stabilized pharmaceutical compositions comprising antibody-drug conjugates and related products and methods, such as to said pharmaceutical compositions for use in therapy, e.g. as cancer therapy. Moreover, the invention relates to the use of specific substances to stabilize antibody conjugate containing pharmaceutical composition.

The present invention provides an anti-BAFFR antibody or an antigen-binding fragment thereof, a nucleic acid molecule encoding the antibody or an antigen-binding fragment thereof, a carrier containing the nucleic acid molecule, a host cell containing the nucleic acid molecule or the carrier, an antibody conjugate containing the antibody molecule, a chimeric antigen receptor, a pharmaceutical composition and a cassette, and their use in the preparation of a medicament for treating cancer or an autoimmune disease.

The application provides anti-CD28 nanobodies and uses thereof, and belongs to the technical field of biotechnology. Specifically disclosed are several CD28-targeted nanobodies, coding sequences and expression vectors for producing the nanobodies, and application of the nanobodies in preparation of tumor treatment drugs. The nanobodies can not only specifically recognize and bind to CD28, laying a foundation for subsequent development of antibody conjugated drugs and multi-specific antibodies, but also can be combined with tumor antigen-targeted antibodies to form multi-specific antibodies, and the formed multi-specific antibodies significantly enhance the ability of activated T cells and the activity of killing tumor cells.

The present application relates to a preparation method for and an application of an antibody conjugated drug, in particular to a compound, or a tautomer, mesomer, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt, prodrug, or solvate thereof, preparation methods of the compound and related antibody conjugated drug, and uses thereof in the preparation of drugs for treating cancers.

The application discloses a Bifidobacterium lactis specific protein antibody, an antibody conjugated magnetic bead and application. The antibody is a monoclonal antibody BL1, comprising a heavy chain variable region and a light chain variable region, and the amino acid sequences of the heavy chain variable region and the light chain variable region are shown in SEQ ID NO: 3 and 4 respectively. The antibody conjugated magnetic bead is coupled by the monoclonal antibody BL1 and activated carboxyl magnetic beads. The antibody conjugated magnetic bead can specifically enrich Bifidobacterium lactis, has high enrichment efficiency, simple enrichment operation, and can be applied to identification of metabolic products of Bifidobacterium lactis, and can be used for qualitative and quantitative analysis.

This invention discloses an antibody against a Bacteroides monoclonal protein, a magnetic bead antibody conjugate, and their applications. The monoclonal antibody is either monoclonal antibody 2F8 or monoclonal antibody 3C10. The amino acid sequences of the heavy chain variable region and light chain variable region of monoclonal antibody 2F8 are shown in SEQ ID NO: 5 and SEQ ID NO: 6, respectively, and the amino acid sequences of the heavy chain variable region and light chain variable region of monoclonal antibody 3C10 are shown in SEQ ID NO: 7 and SEQ ID NO: 8, respectively. The magnetic bead antibody conjugate is obtained by conjugating the monoclonal antibody with activated carboxyl magnetic beads. The magnetic bead antibody conjugate of this invention can specifically enrich Bacteroides monoclonal with high enrichment efficiency and simple enrichment operation. It can be applied to the identification of Bacteroides monoclonal metabolites, as well as their qualitative and quantitative analysis.

The present invention relates to radiolabeled gemtuzumab ozogamicin antibodies and humanized versions conjugated with the radionuclide astatine 211 The antibody conjugates are used in radiotherapy for the treatment of urothelial cancer, including bladder cancer.

The present application relates to a preparation method of a CD20 antibody conjugated drug, the antibody conjugated drug and the use thereof. Specifically, the present application discloses a CD20 antibody conjugated drug as shown in general formula I. The antibody conjugated drug has a significant anti-tumor effect.

The application provides a Mycobacterium tuberculosis EspB monoclonal antibody, a preparation method and application thereof, and relates to the technical field of antibodies. The Mycobacterium tuberculosis EspB monoclonal antibody is obtained by immunizing animals with Mycobacterium tuberculosis cell walls and screening the monoclonal antibody through a phage antibody library technology. The application discloses the Mycobacterium tuberculosis EspB monoclonal antibody or a functional fragment thereof, and application thereof as an antibody conjugate and a composition. The monoclonal antibody has a specific nucleic acid sequence, and codes the specific EspB monoclonal antibody or the functional fragment thereof. The EspB monoclonal antibody obtained by the application has the characteristics of high sensitivity, high specificity and high affinity.

We provide camptothecin-based pharmaceuticals and their antibody conjugates. [Solution] A compound of the following formula I and its antibody complex are provided. JPEG2026086826000042.jpg62170 (In formula I, R1 and R2 are independently a C1-C3 alkyl group, -H, -CF3, aryl group, heteroaryl group, etc.)

Therapeutic antibodies specific for osteopontin and methods of using them for treating osteopontin-associated disorders are provided. In particular, antibodies, or antigen-binding fragments thereof, that inhibit thrombin-cleavage of osteopontin or block the activity of thrombin cleavage fragments of osteopontin are provided. Additionally, antibody conjugates and pharmaceutical compositions or formulations comprising the antibodies or antibody conjugates as well as kits including the antibodies, conjugates, or formulations are also provided.

The present invention relates to a single domain antibody comprising at least one modification relative to the 4D5 antibody scaffold or human germline VH3 domain, said modification being selected from the group consisting of H35D, A78V, S93V, S93G and W103R, wherein the position numbering is according to the Kabat numbering scheme. The disulfide bond free variant further comprises at least one additional modification selected from the group consisting of C22S, A24I, A24L and C92T, with the proviso that at least one of C22S and C92T is present. The present invention also includes multi- modular antibody molecules and antibody conjugates comprising the single domain antibody, and methods of producing them. In particular, the present invention provides libraries of single domain antibodies or multi- modular antibody molecules and methods of selecting antibodies that bind to an antigen.

This invention relates to a novel linker compound of formula (i) disclosed herein. The invention also relates to antibody conjugates. The invention relates to methods which utilise the compounds and conjugates disclosed herein.

Provided herein are methods of treating eye disorders by administering an anti-VEGF antibody and / or conjugate to a subject having an eye disorder. The anti-VEGF antibody of the present disclosure may be an anti-VEGF antibody conjugate that includes a polymeric moiety that extends the half-life / effectiveness / properties of the antibody when administered to a subject. A method of the present disclosure includes administering one or more doses of an anti-VEGF antibody conjugate to a subject (e.g., human or other mammalian patient) in need of treating an eye disorder, where the anti-VEGF antibody conjugate may be administered less frequently than a standard anti-VEGF therapy to treat the eye disorder.

The application discloses a monoclonal antibody DL1 of Dielma bacteria and application thereof, wherein the monoclonal antibody DL1 comprises a DL1 heavy chain and a DL1 light chain, and the monoclonal antibody DL1 is coupled with activated carboxyl magnetic beads to obtain a magnetic bead-antibody conjugate. The magnetic bead-antibody conjugate is used for enrichment, and Dielma bacteria can be enriched to a large extent. The magnetic bead sorting enrichment of Dielma bacteria is selected by using a magnetic force frame, and the method has low cost and small influence on the activity of target bacteria compared with a chip or a flow sorting method. The enriched Dielma bacteria can be applied to the analysis of metabolites of the bacteria, and can also be applied to qualitative or quantitative analysis.

This invention discloses a highly specific and sensitive immunochromatographic test strip, comprising a first conjugation pad, a second conjugation pad, a nitrocellulose membrane coated with C and T lines, an absorption pad, and a base plate. The first conjugation pad is immobilized with antibody A conjugated to oxidized dextran, representing the antigen to be detected. The second conjugation pad is immobilized with ConA-conjugated colloidal gold and anti-DNP antibody conjugated to colloidal gold. The T line is coated with antibody B, representing the antigen to be detected. The C line is coated with DNP. The invention also discloses the preparation method of the test strip, the detection kit, and the detection method. This invention introduces the dextran and ConA system. ConA is a tetrameric globulin, with each subunit containing one sugar-binding site, and each ConA having four sugar-binding sites, thereby enhancing the detection signal, amplifying the signal, and improving detection sensitivity. It is suitable for the detection of various product types and has broad application prospects.

This invention discloses an antibody-drug conjugate (ADC) intermediate hydrochloride and its preparation method. The ADC intermediate hydrochloride has the following structural formula: [structural formula would be inserted here]. The ADC intermediate hydrochloride of this invention has advantages such as high purity (above 98%), stable crystal form, low hygroscopicity, and high chemical stability, maintaining good stability during long-term storage. The preparation method of this invention uses conventional reagents with high safety, eliminating the need for silica gel column chromatography purification; extremely high purity can be obtained simply by recrystallization, making it suitable for large-scale industrial production.

The application discloses an antibody of a specific protein of a bacterium of the genus Ruminococcus and application thereof. The monoclonal antibody of the application is any one of monoclonal antibody 3F, monoclonal antibody 6D, monoclonal antibody 10E and monoclonal antibody 2C, and the monoclonal antibody 3F, the monoclonal antibody 6D, the monoclonal antibody 10E and the monoclonal antibody 2C recognize proteins glgA, glgB, GH18 and pulA respectively. The magnetic bead antibody conjugate is obtained by coupling the monoclonal antibody with activated carboxyl magnetic beads. The magnetic bead antibody conjugate of the application can specifically enrich the bacterium of the genus Ruminococcus, has high enrichment efficiency, is simple in enrichment operation and can be applied to identification of metabolic products of the bacterium of the genus Ruminococcus and also can be used for qualitative and quantitative analysis.

Provided are an anti-CD79B antibody-drug conjugate, and a preparation method therefor and pharmaceutical use thereof. In particular, provided are an antibody-drug conjugate (ADC) which comprises an anti-CD79B antibody conjugated with an MMAE or a derivative thereof, exatecan or a derivative thereof, or Eribulin or a derivative thereof, a pharmaceutical composition containing the ADC, and use thereof in preparation of a drug for treatment of a CD79B-mediated disease or disorder, especially use thereof in preparation of an anti-cancer drug.

Provided herein are antibody-drug conjugates containing an anti-CD24 antibody conjugated to a cytotoxic agent via a linker, in which the antibody selectively binds to human CD24 protein expressed on cancer cells but not human CD24 expressed in non-cancerous cells; and uses thereof for treating cancer.

The application provides a broad-spectrum monoclonal antibody of enterovirus A population and application thereof, and belongs to the technical field of molecular biology and immune analysis. The monoclonal antibody comprises the following six CDR regions: the amino acid sequences of the CDR regions of the heavy chain are respectively shown in SEQ ID No. 1-SEQ ID No. 3; and the amino acid sequences of the CDR regions of the light chain are respectively shown in SEQ ID No. 4-SEQ ID No. 6. The application also provides a nucleotide fragment encoding the monoclonal antibody, a recombinant vector and an engineering cell line comprising the nucleotide fragment, an antibody conjugate and their uses. The monoclonal antibody is a non-neutralizing antibody of IgG1 subtype, can be combined with enterovirus A population viruses in a broad spectrum, and can be used for preparing a reagent or / and a kit for detecting enterovirus A population viruses, and for preparing a medicine for inhibiting, preventing or / and treating enterovirus A population viruses.

The application discloses an antibody conjugated nucleic acid-lipid nanoparticle freeze-drying composition and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The composition contains the antibody conjugated nucleic acid-lipid nanoparticle and a freeze-drying protective agent; the lipid nanoparticle is compounded by using a double-cationic lipid and two PEG conjugated lipids with different structures, and the antibody targets T cell antigens. The application considers the freeze-drying stability, low immunogenicity and high targeting efficacy by the synergy of the two PEG conjugated lipids; the particle size and nucleic acid integrity are kept good before and after freeze-drying, the composition can be stored for a long time at 4 DEG C, can efficiently target T cells, significantly reduce the activation of inflammatory factors and complements, realize a high B cell clearance rate, and is suitable for the preparation of nucleic acid drugs.

This invention discloses a monoclonal antibody against a Bacteroides fragilis-specific protein and its applications, belonging to the field of biotechnology. Using the OmpA and SusD proteins on the surface of Bacteroides fragilis as immunogens, this invention prepares a highly specific monoclonal antibody with strong antigen-binding affinity using hybridoma technology. After conjugating this monoclonal antibody with magnetic beads, the resulting magnetic bead antibody conjugate can efficiently enrich and / or isolate Bacteroides fragilis from treated samples, offering advantages of convenience and low cost. Furthermore, the isolated Bacteroides fragilis can be used for whole-genome sequencing, metabolite analysis, and strain function research, providing new technical means for Bacteroides fragilis microecological research, probiotic preparation quality control, rapid clinical diagnosis, and functional strain screening.